Decades after its launch, NASA’s Voyager spacecraft has made a startling discovery at the edge of our solar system. The probe ...

Voyager is paying travel partner Transition Bio a single-digit million-dollar upfront payment, with additional payments up to ...

Momentum building around tau: expect VY7523 clinical data and VY1706 clinical entry in 2026 - - Sharpened focus on multi-modality pipeline with ...

CAMBRIDGE, United Kingdom and LEXINGTON, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Transition Bio, a drug discovery company focused on unlocking ...

- New program combines IV-delivered TRACER™ capsid with bifunctional payload to silence APOE in carriers of the high-risk APOE4 variant while delivering the protective APOE2 variant - - Voyager’s ...

LEXINGTON, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it has decided to ...

- Additional new data demonstrate VY-TAU01, Voyager’s lead antibody targeting pathological tau, was well-tolerated and demonstrated favorable pharmacokinetics in non-human primates (NHPs) - - Data to ...

- Voyager to receive up-front consideration of $175 million including a $39 million equity investment, up to $1.5 billion in potential development milestones, additional potential commercial ...

- Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad brain distribution and liver de-targeting, in NHP study - - Preclinical ...

For nearly five decades, NASA's twin Voyager probes have plumbed the cosmos in search of answers to some of astronomy's most perplexing mysteries about our solar system and its place in the wider ...

- All other programs remain on track; IND filings expected in 2025 for GBA1 and FA programs - LEXINGTON, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (VYGR), a biotechnology ...